MBBS (Hons).
MD, President, Society of Cardiovascular Computed Tomography; Director, Cardiac Computed Tomography, Brigham and Women@s Hospital, Boston, MA.
Aust J Gen Pract. 2020 Aug;49(8):464-469. doi: 10.31128/AJGP-03-20-5277.
Identifying high-risk asymptomatic individuals remains the cornerstone of cardiovascular disease prevention. Coronary artery calcium is a highly specific marker of atherosclerosis that can be quantified using non-contrast computed tomography. The resulting calcium score has the capacity to improve current methods of risk stratification.
The aim of this article is to provide an overview of calcium scoring, including its method of acquisition, indications, interpretation and role in prognostication.
Calcium score has been shown to convincingly predict future cardiovascular risk in the asymptomatic population across a wide range of ethnicities, ages and sexes. Individuals at intermediate Framingham risk benefit the most from calcium scoring, which can be used to inform the need for preventive pharmacotherapy. Calcium scoring can be repeated after five years to reassess cardiovascular risk, especially when there is a decision to defer statin therapy on the basis of absence of coronary calcium.
识别无症状的高危个体仍然是心血管疾病预防的基石。冠状动脉钙是动脉粥样硬化的高度特异性标志物，可以使用非对比计算机断层扫描进行定量。由此产生的钙分数有能力改善当前的风险分层方法。
本文的目的是概述钙评分，包括其采集方法、适应证、解读和预后作用。
钙评分已被证明在广泛的种族、年龄和性别范围内，在无症状人群中令人信服地预测未来的心血管风险。处于 Framingham 风险中间范围的个体从钙评分中获益最大，可据此确定是否需要预防性药物治疗。可以在五年后重复钙评分以重新评估心血管风险，尤其是在决定根据无冠状动脉钙而推迟使用他汀类药物时。
